meet our
Senior Advisors

The Team That Makes Extraordinary Exits™ Possible

Jeff Massone

Senior Advisor

Jeff Massone is a versatile project management and operations leader with 20 years of experience driving complex, cross-functional initiatives across global pharmaceutical and consumer health organizations. As a Senior Advisor to STS Capital Partners, Jeff leverages his long-standing relationships within the life sciences industry to introduce founders and executives who may benefit from STS’s Selling to Strategics™ approach.​

Jeff Massone

Across his career, Jeff has led programs spanning the full drug development lifecycle, new product commercialization, IT system transformations, and enterprise capability-building. He is known for turning ambiguous, high-level strategies into clear execution roadmaps – aligning diverse stakeholders, establishing governance, and building the processes, tools, and teams required to deliver predictable outcomes. In the M&A and integration context, Jeff’s strength lies in de-risking execution: clarifying decision rights, preserving momentum, and ensuring organizations can realize intended synergies without compromising culture.​

Jeff currently serves as Senior Director of Medical Affairs Project Management & Operations at Kyowa Kirin, where he rebuilt the project management function, elevated departmental performance, and unified Medical Affairs leadership around a shared strategic direction. Previously, at Johnson & Johnson, he accelerated Phase 2 and Phase 3 development timelines across high-value compounds and co-led the design and rollout of the Site Engagement Model, which set new industry benchmarks in clinical trial enrollment.​

Earlier roles include leading digital medicine programs at Otsuka, overseeing global commercialization initiatives at Bayer Consumer Healthcare, managing large-scale product launches and portfolio processes at Merck, and driving operational improvements at Patheon. Throughout these positions, he has directed budgets up to $100M, managed global cross-functional teams, modernized systems and workflows, and contributed to major product divestitures, new revenue lines, and accelerated regulatory filings.​

Jeff holds an MBA from Rutgers Business School and a BS in Animal Science from Rutgers University. He is PMP and CPM certified, a Maxwell Leadership President’s Advisory Council member, and the recipient of multiple innovation and leadership awards from Bayer and Johnson & Johnson. He remains active in his community through board service and mentoring emerging professionals.​

​

Press Releases

Pursant Founder Mark Herbick Joins STS Capital Partners as Chief Executive Officer 

November 2, 2026

STS Capital Partners is pleased to announce that Mark Herbick has been appointed Chief Executive Officer, effective November 1, 2026, as Pursant, the firm he founded, joins forces with STS. A serial e…

Press Releases

Steve Weclew is Appointed by STS Capital Partners as Managing Director

October 29, 2026

We are pleased to announce the appointment of Steve Weclew as a Managing Director.  A CPA by training, former public-company CFO, and co-founder and CEO of an acquisition-led platform, Steve brings…

Press Releases

Former Goddard Enterprises Managing Director Anthony Ali Joins STS Capital Partners as Managing Director and Partner  

October 19, 2026

STS Capital Partners is pleased to announce that Anthony Ali is joining the firm as Managing Director and Partner, bringing extensive international leadership experience and a proven track record in b…

Featured

Thought Leadership

If You’re Considering an ESOP, Run a Competitive Process

October 15, 2026

Why founders should apply the same process to an ESOP as they would to any other buyer. For many founders, the decision to explore an Employee Stock Ownership Plan (ESOP) is not driven by valuation…

Press Releases

Claude Zdanow is Appointed by STS Capital Partners as managing director

September 30, 2026

We are pleased to announce the appointment of Claude Zdanow as a Managing Director.   A public-company CEO, serial founder, and M&A principal, Claude brings nearly two decades of experience building…

Thought Leadership

Building for an Extraordinary Exit™ Starts on Day One

September 15, 2026

Founders rarely begin building a business with an exit in mind.  The early years are consumed by proving an idea, winning customers, preserving cash and creating momentum. Decisions about governance…

Scroll to Top